Treatment target at 6 months: SDAI remission | Sensitivity (when 80% specificity) | 3-month SDAI improvement | PPV | NPV | LR+ | LR− |
All patients | 0.64 | 69.2% | 0.28 | 0.95 | 3.19 | 0.45 |
Baseline SDAI MDA | 0.65 | 64.2% | 0.36 | 0.93 | 3.30 | 0.44 |
Baseline SDAI HDA | 0.79 | 72.7% | 0.22 | 0.98 | 3.96 | 0.26 |
Disease duration ≤12 months | 0.66 | 73.0% | 0.32 | 0.94 | 3.36 | 0.42 |
Disease duration >12 months | 0.68 | 65.8% | 0.27 | 0.96 | 3.40 | 0.40 |
DMARD-naïve starting MTX | 0.65 | 73.0% | 0.32 | 0.94 | 3.30 | 0.44 |
bDMARD-naïve starting TNFi | 0.58 | 73.0% | 0.37 | 0.91 | 2.98 | 0.52 |
Treatment target at
6
months: SDAI low disease activity | ||||||
All patients | 0.53 | 60.2% | 0.70 | 0.66 | 2.65 | 0.59 |
Baseline SDAI MDA | 0.62 | 46.5% | 0.82 | 0.59 | 3.11 | 0.48 |
Baseline SDAI HDA | 0.63 | 65.2% | 0.62 | 0.81 | 3.21 | 0.46 |
Disease duration ≤12 months | 0.48 | 66.0% | 0.73 | 0.58 | 2.51 | 0.64 |
Disease duration >12 months | 0.54 | 55.6% | 0.67 | 0.70 | 2.76 | 0.57 |
DMARD-naïve starting MTX | 0.46 | 66.6% | 0.74 | 0.55 | 2.31 | 0.67 |
bDMARD-naïve starting TNFi | 0.54 | 64.7% | 0.75 | 0.62 | 2.84 | 0.57 |
b, biological; DMARD, disease-modifying antirheumatic drug; HDA, high disease activity; LR+, positive likelihood ratio; LR−, negative likelihood ratio; MDA, moderate disease activity; MTX, methotrexate; NPV, negative predictive value; PPV, positive predictive value; SDAI, Simplified Disease Activity Index; TNFi, tumour necrosis factor inhibitor.